Abdulaziz Radhi S AL Johni*

Department of Laboratory at King Fahad Hospital, Saudi Arabia

*Corresponding Author: Abdulaziz Radhi S AL Johni, Department of Laboratory at King Fahad Hospital, Saudi Arabia.

Received: July 05, 2021 ; Published: August 07, 2021

Abstract

In China, the SARS-CoV-2 coronavirus, also known as the severe acute respiratory syndrome coronavirus (SARS-CoV-2), initially emerged and subsequently spread across the world, resulting in coronavirus disease 19 (COVID-19), a highly infectious and often fatal viral infection.

A genomic study indicates that SARS-like bat viruses, which is known as SARS-CoV-2, are phylogenetically related to SARS-CoV-2, suggesting that bats are the virus's primary host. While the intermediate source of genesis and transfer to humans has yet to be discovered, many investigations have confirmed the rapid transmission from human to human. There is presently no antiviral drug or vaccine that has been clinically approved for use against COVID-19. However, fewer broad-spectrum antiviral medicines have been tried in clinical trials against COVID-19, and only a handful have shown clinical improvement. This research describes and compares the progression and pathogenicity of COVID-19 infection with those of other human coronavirus infections, such as SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) (MERS-CoV). The techniques for developing effective vaccines and therapy combinations to combat the present viral pandemic are also thoroughly addressed.

Keywords: The Genesis and Pathogenicity of the Coronavirus Disease 19 (COVID-19) Infection; The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV); and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (MERS-CoV) Treatment and Vaccine for COVID-19 COVID-19 Saudi Arabia's Madinah Munawara

References

1. Zhu N., et al. “A novel coronavirus from patients with pneumonia in China, 2019”. The New England Journal of Medicine8 (2020): 727-733.
2. Dong E., et al. “An interactive web-based dashboard to track COVID-19 in real time”. Lancet Infectious Disease5 (2020): 533-534.
3. Petrosillo N., et al. “COVID19, SARS and MERS: are they closely related?” Clinical Microbiology and Infection 6 (2020): 729-734.
4. Saudi Arabia Covid-19 Dashboard (2020).
5. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet10229 (2020): 1054-1062.
6. Lai PH., et al. “Characteristics associated with out-of-hospital cardiac arrests and resuscitations during the novel coronavirus disease 2019 pandemic in New York City”. JAMA Cardiology 2020 (2020): e202488.
7. Rezende LFM., et al. “Adults at high-risk of severe coronavirus disease-2019 (Covid-19) in Brazil”. Review Saude Publica 54 (2020): 50.
8. Docherty AB., et al. “Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study”. BMJ 369 (2020).
9. Alsofayan YM., et al. “Clinical characteristics of COVID-19 in Saudi Arabia: a national retrospective study”. Journal of Infection and Public Health (2020): S1876-0341 (20): 30492-5.
10. Sardu C., et al. “Impact of diabetes mellitus on clinical outcomes in patients afected by Covid-19”. Cardiovascular Diabetology1 (2020): 76.
11. Wu Z and McGoogan JM. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention”. JAMA13 (2020): 1239-1242.
12. Reynolds HR., et al. “Renin-angiotensinaldosterone system inhibitors and risk of Covid-19”. The New England Journal of Medicine25 (2020): 2441-2448.
13. Saavedra JM. “Angiotensin receptor blockers and COVID-19”. Pharmacology Research 156 (2020): 104832.
14. Schnell O., et al. “Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group”. Cardiovascular Diabetology1 (2019): 30.
15. Habibi J., et al. “The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat”. Cardiovascular Diabetology1 (2019): 40.
16. Al-Daghri NM., et al. “Diabetes mellitus type 2 and other chronic noncommunicable diseases in the central region, Saudi Arabia (Riyadh cohort 2): a decade of an epidemic”. BMC Medicine 9 (2011): 76.
17. Hussain S., et al. “Burden of diabetes mellitus and its impact on COVID-19 patients: a meta-analysis of real-world evidence”. Diabetes and Metabolic Syndrome 6 (2020): 1595-602.
18. Caballero AE., et al. “COVID-19 in people living with diabetes: an international consensus”. Journal of Diabetes Complications 9 (2020): 107671.
19. Mokdad AH., et al. “When chronic conditions become acute: prevention and control of chronic diseases and adverse health outcomes during natural disasters”. Preventing Chronic Disease 2 (2005): A04.
20. ML Holshue., et al. “First case of 2019 novel coronavirus in the United States”. The New England Journal of Medicine 382 (2020): 929-936.
21. VK Derebail and RJ Falk. “ANCA-associated vasculitis—refining therapy with plasma exchange and glucocorticoids”. Massachusetts Medical Society (2020).
22. Peeri NC., et al. “The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?” International Journal of Epidemiology3 (2020).
23. Organization WH. Rational use of personal protective equipment for coronavirus disease (COVID-19): interim guidance, 27 February 2020. World Health Organization (2020).
24. “Laboratory testing for coronavirus disease (COVID-19) in suspected human cases”. WHO (2020).
25. To KK., et al. “Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study”. Lancet Infectious Disease5 (2020): 565‐574.
26. European Centre for Disease Prevention and Control. An overview of the rapid test situation for COVID-19 diagnosis in the EU/EEA. Stockholm: ECDC (2020).
27. Yang T., et al. “Point-of-Care RNA-based diagnostic device for COVID-19”. Diagnostics3 (2020): 165.
28. UJ Kim., et al. “Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome”. Antivirus Therapy (Lond) 21 (2016): 455-459.
29. E de Wit., et al. “Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection”. Proceedings of the National Academy of Sciences of the United States of America 117 (2020): 6771-6776.
30. P Colson., et al. “Chloroquine and hydroxychloroquine as available weapons to fight COVID-19”. International Journal of Antimicrobial Agents 4 (2020): 105932.
31. F Zaragozá García and M Ibarra Lorente. “Interferon beta as a therapy for múltiple sclerosis”. Farmacia Hospitalaria 26 (2002): 294-301.
32. Villar C Ferrando., et al. “Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial”. Lancet Respiratory Medicine 8 (2020): 267-276.
33. Y Zhou., et al. “Aberrant pathogenic GM-CSF + T cells and inflammatory CD14 + CD16 + monocytes in severe pulmonary syndrome patients of a new coronavirus”. Immunology (2020).
34. A García Roche., et al. “Cytokine release syndrome. Reviewing a new entity in the intensive care unit”. Medicina Intensiva 43 (2019): 480-488.
35. CC Lu., et al. “Potential therapeutic agents against COVID-19: What we know so far”. Journal of the Chinese Medical Association 6 (2020): 534-536.
36. EG Favalli., et al. “Baricitinib for COVID-19: a suitable treatment?”. Lancet Infectious Disease (2020).
37. L Adam Monteagudo., et al. “Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome”. ACR Open Rheumatology5 (2020): 276-282.
38. G Gritti., et al. “Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support”. Respiratory Medicine (2020).
39. L Li., et al. “Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial”. JAMA 5 (2020): 460-470.
40. W Cao., et al. “High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019”. Open Forum Infectious Diseases 7 (2020).

Citation

Citation: Abdulaziz Radhi S AL Johni. “COVID-19 and the Challenges it Poses are Discussed ”. Acta Scientific Microbiology 4.9(2021): 33-43.

Copyright

Copyright: © 2021 Abdulaziz Radhi S AL Johni. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.